Erlotinib Hydrochloride (CP-358774 Hydrochloride) inhibits purified EGFR kinase with an IC50 of 2 nM.
CAS Number: 183319-69-9
Molecular Weight: 429.90
Related CAS Number:
183321-74-6 (Erlotinib free base)
248594-19-6 (Erlotinib mesylate)
Chemical Name: N-(3-ethynylphenyl)-6, 7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO: 4 mg/mLwarmed(9.3 mM).
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
Erlotinib HCl potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi humancolon cancer cells andMDA MB-468 human breast cancer cells. Erlotinib HCl (1 μM) induces apoptosis in DiFi humancolon cancer cells. Erlotinib inhibits growth of a panel of NSCLC cell lines including A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 with IC50 ranging from 29 nM to >20 μM. Erlotinib HCl(2 μM) significantly inhibits growth of AsPC-1 and BxPC-3 pancreatic cells. The effects of Erlotinib HCl in combination with gemcitabine are considered additive in KRAS-mutated pancreatic cancer cells. Ten micromolar of Erlotinib HCl inhibits EGFR phospho-rylation at the Y845 (Src-dependent phosphorylation) and Y1068 (auto-phosphorylation) sites. Combination with Erlotinib HCl could down-modulate rapamycin-stimulated Akt activity and produces a synergistic effect on cell growth inhibition.
At doses of 100 mg/kg, Erlotinib HCl completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice. Erlotinib HCl (100 mg/Kg) inhibits H460a and A549 tumor models with 71 and 93% inhibition rate.
- Moyer JD, et al. Cancer Res. 1997, 57(21), 4838-4848.
- Li T, et al. Clin Cancer Res, 2007, 13(11), 3413-3422.
- Ali S, et al. Mol Cancer Ther, 2008, 7(6), 1708-1719.
- Buck E, et al. Mol Cancer Ther. 2006, 5(11), 2676-2784.
- Higgins B, et al. Anticancer Drugs. 2004, (5), 503-512.
- Furugaki K,et al. Oncol Lett. 2010, 1(2), 231-235.
- Bago-Horvath Z, et al. 2012, DOI: 10.1159/000337257
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.